Scholarlink

Purpose <p>Non-Hodgkin lymphoma (NHL) constitutes 90% of all lymphomas and accounts for 2.8% of new cancer cases and 2.6% of cancer-related deaths in 2020. Hematopoietic stem cell transplantation remains the standard treatment for refractory or relapsed NHL. Due to the shortage of carmustine, this study aimed to compare the outcomes of patients undergoing autologous stem cell transplantation (ASCT) with conditioning regimens that either include or exclude this drug over an 11-year period.</p> Methods <p>This retrospective study included a cohort of 240 patients with NHL who underwent ASCT with an EAM conditioning regimen, both with and without carboplatin. Following informed consent, clinical data from patients who underwent transplantation between March 2006 and May 2017 were collected. Patients were followed to assess overall survival (OS) and disease-free survival (DFS) as primary endpoints.</p> Results <p>No significant differences were observed between the survival outcomes of the two groups with differing conditioning regimens (<i>P</i> = 0.27 for OS; <i>P</i> = 0.49 for DFS). The 3-year and 5-year OS rates were 81% and 74.8%, respectively, with a median follow-up of 74 months. The 3-year and 5-year DFS rates were 66.6% and 62.1%, respectively. OS and DFS were significantly higher in patients with B-cell lymphomas compared to those with T-cell lymphoma (<i>P</i> &lt; 0.01).</p> Conclusion <p>Our real-world data indicate that the addition of carboplatin to the EAM conditioning regimen does not significantly affect survival outcomes for patients with NHL undergoing ASCT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Autologous bone marrow transplantation in non-Hodgkin lymphoma patients following different conditioning regimens: an 11-year single-center quasi-experimental study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月9日

查看全文
  • Sahar Tavakoli Shiraji,
  • Mohammad Biglari,
  • Soroush Rad,
  • Maryam Barkhordar,
  • Hossein Kamranzadeh Foumani,
  • Ghasem Janbabaei,
  • Seied Asadollah Mousavi,
  • Mohammad Vaezi,
  • Kamran Mohammadi,
  • Ardeshir Ghavamzadeh

摘要

Purpose

Non-Hodgkin lymphoma (NHL) constitutes 90% of all lymphomas and accounts for 2.8% of new cancer cases and 2.6% of cancer-related deaths in 2020. Hematopoietic stem cell transplantation remains the standard treatment for refractory or relapsed NHL. Due to the shortage of carmustine, this study aimed to compare the outcomes of patients undergoing autologous stem cell transplantation (ASCT) with conditioning regimens that either include or exclude this drug over an 11-year period.

Methods

This retrospective study included a cohort of 240 patients with NHL who underwent ASCT with an EAM conditioning regimen, both with and without carboplatin. Following informed consent, clinical data from patients who underwent transplantation between March 2006 and May 2017 were collected. Patients were followed to assess overall survival (OS) and disease-free survival (DFS) as primary endpoints.

Results

No significant differences were observed between the survival outcomes of the two groups with differing conditioning regimens (P = 0.27 for OS; P = 0.49 for DFS). The 3-year and 5-year OS rates were 81% and 74.8%, respectively, with a median follow-up of 74 months. The 3-year and 5-year DFS rates were 66.6% and 62.1%, respectively. OS and DFS were significantly higher in patients with B-cell lymphomas compared to those with T-cell lymphoma (P < 0.01).

Conclusion

Our real-world data indicate that the addition of carboplatin to the EAM conditioning regimen does not significantly affect survival outcomes for patients with NHL undergoing ASCT.